BOLD - Audentes Therapeutics, Inc.
| Previous Close | 36.90 |
| Open | 36.86 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 35.47 - 36.86 |
| 52 Week Range | 17.95 - 46.18 |
| Volume | 437,988 |
| Avg. Volume | 535,518 |
| Market Cap | 1.579B |
| Beta (3Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.40 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.64 |
- Investor's Business Daily•7 days ago
Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.
- Investopedia•16 days ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- PR Newswire•17 days ago
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on March 7, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to six individuals hired by Audentes in February 2019. One-fourth of the shares underlying each employee's option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee's continued employment with Audentes on such vesting dates.
- Simply Wall St.•17 days ago
Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year
It is doubtless a positive to see that the Audentes Therapeutics, Inc. (NASDAQ:BOLD) share price has gained some 39% in the last three months. But in truth the last yearRead More...
- Zacks•19 days ago
Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
Audentes Therapeutics (BOLD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Audentes Therapeutics Inc Earnings Call
- GuruFocus.com•23 days ago
Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018
Audentes Therapeutics Inc (NASDAQ:BOLD) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
- PR Newswire•26 days ago
Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare Disease Day® with the launch of "Be Bold for Courageous Patients," a program designed to meaningfully impact the lives of patients living with rare diseases. "Be Bold for Courageous Patients" is intended to enhance and expand the Company's commitment to rare disease patients and their families. As part of this year's effort, Audentes will provide a sponsorship grant to help support children from the rare disease community to attend The Painted Turtle and Double H Ranch, medical specialty camps that offer the opportunity for kids to enjoy being kids in a camp environment specifically built for their needs. Children and their families will attend The Painted Turtle during Neuromuscular and Genetic Family Weekend from March 1 – 3, in Lake Hughes, California, or Double H Ranch during Camp Inspiration for children who are BIPAP or ventilator dependent from June 7 – 11, in Lake Luzerne, New York.
Motley Fool•26 days agoAudentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call Transcript
BOLD earnings call for the period ending December 31, 2018.
- PR Newswire•26 days ago
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019 On track to submit ...
- Zacks•28 days ago
Biotech ETFs Jump on Roche-Spark Deal
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
- PR Newswire•last month
Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- PR Newswire•last month
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Feb. 20, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- GlobeNewswire•last month
Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners — Future Expectations, Projections Moving into 2019
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Kiplinger•2 months ago
Mizuho's 9 Best Biotech Stocks to Buy for 2019
Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
- PR Newswire•2 months ago
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
SAN FRANCISCO, Jan. 31, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update following the receipt of minutes from its Regenerative Medicine and Advanced Therapy (RMAT)/Type B meeting with the U.S. Food and Drug Administration (FDA) held in December 2018, regarding the company's lead gene therapy candidate, AT132, for the treatment of X-linked Myotubular Myopathy (XLMTM).
- PR Newswire•3 months ago
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
- Completed productive initial interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to discuss potential registration pathways for AT132 for the treatment ...
- PR Newswire•3 months ago
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients ...
- PR Newswire•3 months ago
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 2, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with ...
- Simply Wall St.•3 months ago
Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Insider Monkey•3 months ago
Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- American City Business Journals•3 months ago
Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
